US 11,053,308 B2
Method for treating IL-8-related diseases
Ayako Kakiuchi, Kanagawa (JP); Atsuhiko Kato, Shizuoka (JP); Shuji Hayashi, Shizuoka (JP); Izumi Yanagisawa, Kanagawa (JP); Ryo Konno, Saitama (JP); Sachiho Netsu, Saitama (JP); and Tadashi Sankai, Ibaraki (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP); Jichi Medical University, Saitama (JP); and National Institutes of Biomedical Innovation, Health and Nutritition, Osaka (JP)
Appl. No. 16/323,142
Filed by CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP); JICHI MEDICAL UNIVERSITY, Tokyo (JP); and NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, Osaka (JP)
PCT Filed Aug. 4, 2017, PCT No. PCT/JP2017/028346
§ 371(c)(1), (2) Date Feb. 4, 2019,
PCT Pub. No. WO2018/025982, PCT Pub. Date Feb. 8, 2018.
Claims priority of application No. JP2016-154174 (JP), filed on Aug. 5, 2016.
Prior Publication US 2019/0169286 A1, Jun. 6, 2019
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61P 15/00 (2006.01); A61P 29/00 (2006.01); A61P 11/00 (2006.01); A61K 45/00 (2006.01); A61P 1/16 (2006.01); A61P 13/12 (2006.01); A61P 43/00 (2006.01); A61P 17/06 (2006.01); A61P 15/08 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61P 1/16 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 15/08 (2018.01); A61P 17/06 (2018.01); A61P 29/00 (2018.01); A61P 43/00 (2018.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 16/24 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 9 Claims
 
1. A method for treating an IL-8-related disease, which comprises administering an anti-IL-8 antibody that binds to human IL-8 to a subject in need thereof,
wherein the IL-8-related disease is selected from endometriosis and dysmenorrhea; and
wherein the anti-IL-8 antibody comprises:
(a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1,
(b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2,
(c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3,
(d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1,
(e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and
(f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3.